MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Vaxcyte Inc

Ouvert

SecteurSoins de santé

33.63 1.75

Résumé

Variation du prix de l'action

24h

Actuel

Min

32.92

Max

34.42

Chiffres clés

By Trading Economics

Revenu

-34M

-137M

BPA

-1.018

Employés

414

EBITDA

87M

-53M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+274.34% upside

Dividendes

By Dow Jones

Prochains Résultats

6 mai 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-6.3B

3.9B

Ouverture précédente

31.88

Clôture précédente

33.63

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Vaxcyte Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mars 2025, 14:19 UTC

Principaux Mouvements du Marché

Vaccine Stocks Fall After Ousting of FDA's Vaccine Head

3 sept. 2024, 17:22 UTC

Actualités

Pfizer Better Watch Out for This Biotech -- Heard on the Street-- WSJ

Comparaison

Variation de prix

Vaxcyte Inc prévision

Objectif de Prix

By TipRanks

274.34% hausse

Prévisions sur 12 Mois

Moyen 124.13 USD  274.34%

Haut 160 USD

Bas 65 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

11 ratings

11

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

30.39 / N/ASupport & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vaxcyte Inc

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.